Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output.

PubWeight™: 1.11‹?› | Rank: Top 10%

🔗 View Article (PMC 3744065)

Published in Hepatology on October 01, 2011

Authors

Anna Baghdasaryan1, Thierry Claudel, Judith Gumhold, Dagmar Silbert, Luciano Adorini, Aldo Roda, Stefania Vecchiotti, Frank J Gonzalez, Kristina Schoonjans, Mario Strazzabosco, Peter Fickert, Michael Trauner

Author Affiliations

1: Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.

Articles citing this

Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice. Hepatology (2015) 1.65

Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res (2012) 1.55

Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol (2012) 1.30

Novel therapeutic targets in primary biliary cirrhosis. Nat Rev Gastroenterol Hepatol (2015) 1.01

Nuclear Receptors as Therapeutic Targets in Liver Disease: Are We There Yet? Annu Rev Pharmacol Toxicol (2016) 0.93

Nonalcoholic Fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective. Oxid Med Cell Longev (2014) 0.92

Nuclear receptors as drug targets in cholestatic liver diseases. Clin Liver Dis (2013) 0.91

Clinical application of transcriptional activators of bile salt transporters. Mol Aspects Med (2013) 0.87

Bile Acid Metabolism and Signaling in Cholestasis, Inflammation, and Cancer. Adv Pharmacol (2015) 0.85

Pharmacology of bile acid receptors: Evolution of bile acids from simple detergents to complex signaling molecules. Pharmacol Res (2015) 0.84

The role of LncRNA H19 in gender disparity of cholestatic liver injury in Mdr2(-/-) mice. Hepatology (2017) 0.81

Cystic fibrosis related liver disease--another black box in hepatology. Int J Mol Sci (2014) 0.81

Recent advances in understanding and managing cholestasis. F1000Res (2016) 0.79

Digestive physiology of the pig symposium: intestinal bile acid sensing is linked to key endocrine and metabolic signaling pathways. J Anim Sci (2013) 0.78

Advances in pharmacotherapy for primary biliary cirrhosis. Expert Opin Pharmacother (2014) 0.78

In vitro evidence of possible influence of scutellarein towards bile acids' metabolism. Afr Health Sci (2013) 0.77

Bile acid receptors and nonalcoholic fatty liver disease. World J Hepatol (2015) 0.77

Therapeutic targets for cholestatic liver injury. Expert Opin Ther Targets (2015) 0.76

Novel bile acid therapeutics for the treatment of chronic liver diseases. Therap Adv Gastroenterol (2016) 0.76

Liver Capsule: FXR agonists against liver disease. Hepatology (2016) 0.75

Genetics of primary sclerosing cholangitis and pathophysiological implications. Nat Rev Gastroenterol Hepatol (2017) 0.75

Reversal of liver cirrhosis: current evidence and expectations. Korean J Intern Med (2017) 0.75

A Dual Agonist of Farnesoid X Receptor (FXR) and the G protein-coupled Receptor TGR5, INT-767, Slows Down Age-Related Kidney Disease in Mice. J Biol Chem (2017) 0.75

Embryonic cholecystitis and defective gallbladder contraction in the Sox17-haploinsufficient model of biliary atresia. Development (2017) 0.75

Novel treatment options for portal hypertension. Gastroenterol Rep (Oxf) (2017) 0.75

Articles cited by this

Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab (2005) 9.14

Identification of a nuclear receptor for bile acids. Science (1999) 7.81

Bile acids: natural ligands for an orphan nuclear receptor. Science (1999) 7.18

TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab (2009) 6.91

Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell (2000) 6.71

A G protein-coupled receptor responsive to bile acids. J Biol Chem (2003) 4.76

Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell (1993) 4.76

Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell (1999) 4.76

Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov (2008) 4.43

Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res (2007) 3.84

Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun (2002) 3.41

A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol Cell (2003) 2.85

A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem (1981) 2.85

Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut (2011) 2.57

Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest (2003) 2.51

The cholangiopathies: disorders of biliary epithelia. Gastroenterology (2004) 2.38

Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology (2004) 2.02

Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology (1997) 1.92

Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol (2009) 1.87

Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology (2008) 1.87

6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem (2002) 1.85

Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun (2008) 1.83

Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J Biol Chem (2000) 1.75

Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation. Biochem J (2006) 1.70

The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology (2007) 1.69

Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. Gut (2010) 1.63

The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology (2009) 1.62

Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol (2005) 1.62

24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology (2006) 1.54

Carbonic anhydrase II binds to the carboxyl terminus of human band 3, the erythrocyte C1-/HCO3- exchanger. J Biol Chem (1998) 1.51

Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology (2007) 1.46

The extracellular component of a transport metabolon. Extracellular loop 4 of the human AE1 Cl-/HCO3- exchanger binds carbonic anhydrase IV. J Biol Chem (2002) 1.42

Functional importance of ICAM-1 in the mechanism of neutrophil-induced liver injury in bile duct-ligated mice. Am J Physiol Gastrointest Liver Physiol (2003) 1.40

Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology (2001) 1.32

Immunohistochemical detection of chloride/bicarbonate anion exchangers in human liver. Hepatology (1994) 1.32

The bicarbonate transport metabolon. J Enzyme Inhib Med Chem (2004) 1.30

Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. J Med Chem (2009) 1.29

Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proc Natl Acad Sci U S A (2006) 1.27

Effects of FXR in foam-cell formation and atherosclerosis development. Biochim Biophys Acta (2006) 1.26

Interactions of transmembrane carbonic anhydrase, CAIX, with bicarbonate transporters. Am J Physiol Cell Physiol (2007) 1.25

Nuclear export of retinoid X receptor alpha in response to interleukin-1beta-mediated cell signaling: roles for JNK and SER260. J Biol Chem (2006) 1.21

The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology (2010) 1.16

Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem (2002) 1.14

Primary culture of cholangiocytes from normal mouse liver. In Vitro Cell Dev Biol Anim (1998) 1.12

Bile acid-induced apoptosis in hepatocytes is caspase-6-dependent. J Biol Chem (2008) 1.08

Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Mol Pharmacol (2010) 1.08

Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One (2010) 1.07

Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: in vitro studies in rat hepatocytes and human erythrocytes. Hepatology (1991) 1.04

The membrane-bound bile acid receptor TGR5 (Gpbar-1) is localized in the primary cilium of cholangiocytes. Biol Chem (2010) 1.01

Identification of gene-selective modulators of the bile acid receptor FXR. J Biol Chem (2002) 1.00

Membrane-bound carbonic anhydrase IV is expressed in the luminal plasma membrane of the human gallbladder epithelium. Hepatology (1996) 0.99

Regulation of activity and apical targeting of the Cl-/HCO3- exchanger in rat hepatocytes. Proc Natl Acad Sci U S A (1994) 0.95

Transmembrane carbonic anhydrase, MN/CA IX, is a potential biomarker for biliary tumours. J Hepatol (2001) 0.94

Bicarbonate homeostasis in excitable tissues: role of AE3 Cl-/HCO3- exchanger and carbonic anhydrase XIV interaction. Am J Physiol Cell Physiol (2009) 0.93

The plasma membrane carbonic anhydrase in murine hepatocytes identified as isozyme XIV. BMC Gastroenterol (2002) 0.92

Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells. J Clin Invest (2008) 0.92

Shared apical sorting of anion exchanger isoforms AE2a, AE2b1, and AE2b2 in primary hepatocytes. Biochem Biophys Res Commun (2004) 0.92

Carbonic anhydrases CA4 and CA14 both enhance AE3-mediated Cl--HCO3- exchange in hippocampal neurons. J Neurosci (2009) 0.92

Guidelines for therapy of autoimmune liver disease. Semin Liver Dis (2007) 0.88

High-performance liquid chromatographic-electrospray mass spectrometric analysis of bile acids in biological fluids. J Chromatogr B Biomed Appl (1995) 0.87

Bicarbonate secretion of mouse cholangiocytes involves Na(+)-HCO(3)(-) cotransport in addition to Na(+)-independent Cl(-)/HCO(3)(-) exchange. Hepatology (2010) 0.87

VPAC1 expression is regulated by FXR agonists in the human gallbladder epithelium. Hepatology (2005) 0.84

Hydrophilic bile salts enhance differential distribution of sphingomyelin and phosphatidylcholine between micellar and vesicular phases: potential implications for their effects in vivo. J Hepatol (2001) 0.83

Molecular dynamics simulation of the ligand binding domain of farnesoid X receptor. Insights into helix-12 stability and coactivator peptide stabilization in response to agonist binding. J Med Chem (2005) 0.80

Articles by these authors

Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature (2006) 9.36

Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem (2008) 7.71

TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab (2009) 6.91

C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev (2002) 6.46

Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest (2007) 4.86

Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology (2006) 4.70

Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov (2008) 4.43

Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis. Proc Natl Acad Sci U S A (2003) 4.34

Sex-specific prevalence of adenomas, advanced adenomas, and colorectal cancer in individuals undergoing screening colonoscopy. JAMA (2011) 4.21

Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem (2004) 4.10

ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1. Nat Med (2011) 3.96

Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem (2003) 3.90

Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res (2007) 3.84

Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A (2006) 3.77

Adipose triglyceride lipase contributes to cancer-associated cachexia. Science (2011) 3.70

Loss of ARNT/HIF1beta mediates altered gene expression and pancreatic-islet dysfunction in human type 2 diabetes. Cell (2005) 3.52

The NAD(+)/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial UPR and FOXO Signaling. Cell (2013) 3.50

International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev (2006) 3.48

PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci U S A (2006) 3.29

Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J Biol Chem (2002) 3.24

The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab (2012) 3.18

Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet (2010) 3.15

Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest (2003) 3.09

Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol (2002) 3.02

Sedation in screening colonoscopy: impact on quality indicators and complications. Am J Gastroenterol (2012) 2.97

Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol (2012) 2.93

Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest (2003) 2.87

Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol (2013) 2.85

REV-ERBalpha participates in circadian SREBP signaling and bile acid homeostasis. PLoS Biol (2009) 2.76

NCoR1 is a conserved physiological modulator of muscle mass and oxidative function. Cell (2011) 2.75

Role of the hepatocyte nuclear factor 4alpha in control of the pregnane X receptor during fetal liver development. Hepatology (2003) 2.70

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology (2013) 2.70

Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. Gastroenterology (2011) 2.67

Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology (2002) 2.64

Sirtuins: the 'magnificent seven', function, metabolism and longevity. Ann Med (2007) 2.64

The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology (2013) 2.63

Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology (2012) 2.62

Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases. Hepatology (2006) 2.61

Hepatic steatosis in leptin-deficient mice is promoted by the PPARgamma target gene Fsp27. Cell Metab (2008) 2.57

Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut (2011) 2.57

Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci U S A (2005) 2.56

The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med (2002) 2.45

CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology (2005) 2.45

Modification of ocular defects in mouse developmental glaucoma models by tyrosinase. Science (2003) 2.41

PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci U S A (2003) 2.40

Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage. Hepatology (2004) 2.40

Sirtuin functions in health and disease. Mol Endocrinol (2007) 2.38

The cholangiopathies: disorders of biliary epithelia. Gastroenterology (2004) 2.38

The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem (2006) 2.38

von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology (2012) 2.36

Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J Biol Chem (2011) 2.35

Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J Immunol (2003) 2.32

Synergy between LRH-1 and beta-catenin induces G1 cyclin-mediated cell proliferation. Mol Cell (2004) 2.31

Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat. Cell Metab (2010) 2.30

Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev (2004) 2.30

Radiation metabolomics. 1. Identification of minimally invasive urine biomarkers for gamma-radiation exposure in mice. Radiat Res (2008) 2.27

LRH-1: an orphan nuclear receptor involved in development, metabolism and steroidogenesis. Trends Cell Biol (2004) 2.24

A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes (2002) 2.24

Plasticity and expanding complexity of the hepatic transcription factor network during liver development. Genes Dev (2006) 2.23

Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis (2006) 2.18

TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab (2011) 2.17

C/EBPalpha regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism. Cross-talk between C/EBP pathway and iron metabolism. J Biol Chem (2002) 2.16

Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial. J Am Coll Cardiol (2012) 2.11

Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. Cell Metab (2009) 2.09

The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer (2012) 2.06

Histone methyl transferases and demethylases; can they link metabolism and transcription? Cell Metab (2010) 2.04

Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J Biol Chem (2003) 2.04

Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology (2004) 2.02

A natural product that lowers cholesterol as an antagonist ligand for FXR. Science (2002) 1.99

The pollutant diethylhexyl phthalate regulates hepatic energy metabolism via species-specific PPARalpha-dependent mechanisms. Environ Health Perspect (2010) 1.98

The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem (2002) 1.97

The metabolic footprint of aging in mice. Sci Rep (2011) 1.93

Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat Med (2004) 1.92

A chemical-genetic approach to study G protein regulation of beta cell function in vivo. Proc Natl Acad Sci U S A (2009) 1.90

Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol Cell Biol (2007) 1.90

APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci U S A (2002) 1.89

Compromised intestinal lipid absorption in mice with a liver-specific deficiency of liver receptor homolog 1. Mol Cell Biol (2007) 1.89

Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol (2009) 1.87

The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol (2011) 1.87

Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics (2003) 1.85

Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality. J Clin Invest (2007) 1.85

Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J Med Chem (2008) 1.85

Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J Hepatol (2003) 1.85

The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem (2005) 1.85

Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun (2013) 1.84

Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology (2005) 1.84

Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut (2012) 1.83

Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3. Blood (2005) 1.83

A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol (2007) 1.83

The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med (2003) 1.81

The genetic ablation of SRC-3 protects against obesity and improves insulin sensitivity by reducing the acetylation of PGC-1{alpha}. Proc Natl Acad Sci U S A (2008) 1.80

Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis (2010) 1.79